Abbott (ABT) sues Teva (TEVA) over its drug for kidney patients, Zemplar
More News related to ABT
- Abbott (ABT) Seeks for ARCHITECT HE4 to be First Automated HE4 Test Available in the U.S.
- Abbott Submits New Automated Ovarian Cancer Test for U.S. Approval
- Health Discovery Corporation Partners with Major New York City Pancreatic Cancer Center to Develop a New Molecular Diagnostic Test for the Early Detection of Pancreatic Cancer
- First Global Upgrades Abbot Labs (ABT) to Long Term Outperform
- Absolute Software's Computer Lifecycle Management Solution Selected by University of Texas
More News related to TEVA
- BioSante Pharmaceuticals Appoints Jeffrey W. Winkelman, Ph.D., J.D., Vice President, Oncology Programs
- Teva Pharma (TEVA) Extends Oral Laquinimod Marketing and Distribution Rights to Nordic and Baltic Regions
- Teva Acquires Marketing Rights for Oral Laquinimod in the Nordic and Baltic Regions
- Teva Pharma (TEVA) Settles with Ven-A-Care; To Record Charge of $315M for Q409
- Teva Announces Settlement in Principle regarding Certain Drug Pricing Lawsuits
More News related to Corporate News
- S&P Announces Change to US Index: TSRA for FIF
- RealNetworks (RNWK) and MTV Networks (VIA-B) to Split Off Joint Venture Rhapsody
- Watts Water (WTS) Board Approves Restructuring Program; Shutting Down 3 Plants, Cutting 95 Jobs
- Transcept Pharmaceuticals (TSPT) Granted U.S. Patent Covering Intermezzo Formulation
- AAR (AIR) Predicts Impact of Mesa's Bankruptcy on Q3 Results
Abbott Labs (NYSE: ABT) sues Teva Pharma (Nasdaq: TEVA) over its drug for kidney patients, Zemplar
Related Categories
Corporate NewsStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
